RxDoctor Payments DataLook up a doctor →

Sergio Chang Figueroa, MD

Endocrinology, Diabetes & Metabolism · Madisonville, KYNPI 1447498522

Payments from drug & device makers

$1,240,551in general payments, 2019–2025

Across 2,806 payments — averaging $442.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$392K
  • Novo Nordisk$288K
  • Bayer$228K
  • Boehringer Ingelheim$113K
  • Abbott$76K
  • Sanofi-aventis U.S. LLC$62K
  • plus $82K from 33 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC774$391,568
Novo Nordisk369$287,970
Bayer272$228,189
Boehringer Ingelheim254$112,621
Abbott155$75,819
Sanofi-aventis U.S. LLC139$61,917
Mannkind Corporation287$38,208
Johnson & Johnson40$22,248
Corcept Therapeutics74$13,067
Medtronic(2 entities)117$3,799
Amgen(2 entities)55$906
Tandem Diabetes Care, Inc.36$707
AbbVie29$512
Insulet Corporation47$495
Novartis24$378
AstraZeneca(2 entities)24$375
Amarin Pharma, Inc.17$240
BETA Bionics, Inc.13$240
Merck14$200
Ascensia Diabetes Care US Inc.5$126
Kyowa Kirin, Inc.7$124
Dexcom, Inc.7$115
Radius Health, Inc.6$104
Xeris Pharmaceuticals, Inc.6$97
Astellas Pharma US Inc5$87
Ascendis Pharma Endocrinology Inc4$68
Pfizer3$46
Clarus Therapeutics Inc.4$45
Zealand Pharma US, Inc.3$44
Amryt Pharma Holdings Ltd3$35
Companion Medical, Inc.2$32
Antares Pharma, Inc.2$31
Neurocrine Biosciences, Inc.1$27
Shire North American Group Inc2$26
IBSA Pharma Inc.2$26
Averitas Pharma Inc.1$18
Sequel Med Tech, LLC1$18
Takeda Pharmaceuticals U.S.A., Inc.1$15
Kowa Pharmaceuticals America, Inc.1$11

How this compares

$1,240,551 in reported general payments places this provider in the 95th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.

See all endocrinology, diabetes & metabolism providers in Kentucky →

Medicare billing

Part B allowed, 2024
$110,740
Medicare patients
412
Services billed
3,536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Madisonville

See the full list for Kentucky →

Where these figures come from

Is this you, or does something look wrong? →